
Saag KG, Wagman RB, Geusens P, et al. Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study. Lancet Diabetes Endocrinol. 2018, 6(6):445-454. doi: 10.1016/S2213-8587(18)30075-5.
Advertisement
Articles by Saag KG, Wagman RB, Geusens P, et al. Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study. Lancet Diabetes Endocrinol. 2018, 6(6):445-454. doi: 10.1016/S2213-8587(18)30075-5.

Advertisement
Latest Updated Articles
- Conditional Economic Incentives Could Be Effective in Improving Adherence to Long-Acting PrEP in Transgender Adults
Published: August 18th 2025 | Updated: August 25th 2025
- Semaglutide Not Associated With Increased Risk of Eye Disorders
Published: August 19th 2025 | Updated: August 22nd 2025
- Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
Published: June 6th 2025 | Updated: August 18th 2025
- Report Reveals Mounting Burdens of Drug Shortages on US Health System
Published: June 27th 2025 | Updated: July 1st 2025
- Managed Care Reflections: Insights From Richard J. Gilfillan, MD; and Donald M. Berwick, MD, MPP
Published: February 20th 2025 | Updated: February 21st 2025
- FDA Proposal Aims to Reduce Smoking Addiction and SCLC Cases
Published: January 16th 2025 | Updated: January 29th 2025
Advertisement
Advertisement
Trending on AJMC
1
West Coast Health Alliance Releases First Vaccine Guidelines, Aiming to Replace CDC Recommendations
2
Metabolic Issues More Common in Patients With HIV
3
Hospitals in Underserved Communities Less Likely to Adopt Health Information Technology
4
Sotatercept Shows Right Heart Gains in PAH: Anjali Vaidya, MD
5